Spinoff company BioVersys announces investment in clinical development of its lead asset BV100 in China

On 11 September, D-BSSE spinoff BioVersys announces the investment of US$6m by investment firm Guangzhou-Israel Biotechnology Fund. This investment aligns with BioVersys’ strategic decision to expand its BV100 clinical programme in China. BV100 is a novel formulation of rifabutin suitable for intravenous administration which is targeting specific Acinetobacter baumannii - bacteria, an opportunistic pathogen in humans, typically infecting critically ill and immunocompromised patients.